GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Clinical trials for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR explained in plain language.
Never miss a new study
Get alerted when new GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR trials appear
Sign up with your email to follow new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radioactive drug takes aim at Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase trial tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The drug delivers a powerful radioactive particle directly to cancer cells. The study aims to find the safe…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE1 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New Alpha-Particle therapy targets Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a new drug called [212Pb]VMT-α-NET, which delivers a powerful type of radiation (alpha particles) directly to tumor cells that have a specific marker (SSTR2). The trial includes 300 adults with advanced neuroendocrine tumors or meningioma that cannot be removed b…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Perspective Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New radioactive drug aims to fight gut tumors that resist standard therapy
Disease control Recruiting nowThis study tests a new drug called RYZ101 in people with advanced neuroendocrine tumors (GEP-NETs) that have grown after prior radiation therapy. The trial has two parts: first finding the right dose, then comparing RYZ101 to standard treatments like everolimus or sunitinib. Abou…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE3 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New registry tracks PRRT outcomes for neuroendocrine cancer patients
Disease control Recruiting nowThis study is tracking 50 adults with neuroendocrine tumors who are receiving peptide receptor radionuclide therapy (PRRT). Researchers are collecting data on patient characteristics, treatment responses, survival, and side effects. The goal is to better understand who benefits f…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Sponsor: Methodist Health System • Aim: Disease control
Last updated Jun 27, 2026 11:04 UTC
-
New combo attack: radiation plus surgery for stubborn tumors
Disease control Recruiting nowThis early-phase study is testing whether giving a radioactive drug called Lutathera both before and after surgery is safe for people with advanced neuroendocrine tumors that have spread to the liver or lymph nodes. The trial will enroll 10 adults whose tumors are considered remo…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 26, 2026 15:13 UTC
-
Ultrasound breakthrough: predicting cancer therapy success without needles
Knowledge-focused Recruiting nowThis study is testing whether a special type of ultrasound (called D-CEUS) can predict if a targeted radiation therapy (PRRT) is working in people with advanced neuroendocrine tumors of the pancreas or gut. About 30 adults with these tumors will get D-CEUS scans before, during, a…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: NA • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Could better nutrition help fight Slow-Growing tumors?
Knowledge-focused Recruiting nowThis study at Strasbourg University Hospital will check the nutritional status of 100 adults with gastroenteropancreatic neuroendocrine tumors. Researchers want to see if malnutrition is linked to worse outcomes. The goal is to understand whether improving nutrition could help pa…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
AI and PET-MRI scans aim to personalize cancer radiation therapy
Knowledge-focused Recruiting nowThis study is looking at people with a rare type of digestive system cancer called GEP-NET who are receiving a targeted radiation therapy (PRRT). Researchers will use special PET-MRI scans and artificial intelligence to find patterns that predict how well the treatment works. The…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC